After an entire year of successful collaboration with the leading digital microfluidics company Kapplex, we took action in response to the great fit our technologies and teams and decided to become one company.

Through this, Miroculus IP portfolio grows to over 20 patents in 8 different patent families. This will enable us to automate and simplify the detection of microRNAs from blood using Kapplex’ technology, significantly reducing the cost of the tests and fully automating the assay.

Visit GenomeWeb to read the complete story